Ricardo Menegatti | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Ricardo Menegatti | Pharmaceutical Science | Best Researcher Award

Associate Professor and UFG, Brazil

Assoc. Prof. Dr. Ricardo Menegatti is an Associate Professor at the Faculty of Pharmacy, Federal University of Goiás (UFG), Brazil. His academic journey began with a Bachelor’s degree in Pharmacy from the Federal University of Santa Catarina (UFSC), followed by a Master’s degree in Chemistry and a Ph.D. in Chemistry from the Federal University of Rio de Janeiro (UFRJ). His doctoral research focused on the design, synthesis, and pharmacological evaluation of novel neuroactive drug prototypes. Dr. Menegatti’s expertise spans various aspects of medicinal chemistry, including the development of new pharmacological agents, medicinal chemistry, and pharmaceutical analysis. He has been actively involved in teaching and research since joining UFG in 2006, where he has contributed to the development of courses in medicinal chemistry, pharmaceutical analysis, and organic chemistry. His work also includes extensive contributions to the university’s extension activities, such as coordinating workshops and seminars on pharmaceutical chemistry. Dr. Menegatti has a robust record of publications and presentations in his field, and his research interests primarily revolve around the synthesis of novel pharmacological agents and the application of advanced chemical techniques in drug development.

Profile
Education

Dr. Ricardo Menegatti holds a distinguished educational background in the field of pharmacy and chemistry. He earned his Bachelor’s degree in Pharmacy from the Federal University of Santa Catarina (UFSC) in 1998, where his research focused on leprosy. He then pursued advanced studies at the Federal University of Rio de Janeiro (UFRJ), obtaining a Master’s degree in Chemistry in 2001. His master’s research, under the guidance of Eliezer Jesus Barreiro, involved the design, synthesis, and pharmacological evaluation of new antipsychotic drug candidates, specifically targeting schizophrenia. Dr. Menegatti further advanced his expertise by completing a Ph.D. in Chemistry at UFRJ in 2005, focusing on the planning, synthesis, and pharmacological assessment of neuroactive drug prototypes, particularly in the areas of GABA, hypnotics, and analgesics. His doctoral research, also mentored by Eliezer J. Barreiro, was supported by the National Council for Scientific and Technological Development (CNPq), reflecting his commitment to advancing pharmaceutical sciences.

Professional Experience

Dr. Ricardo Menegatti is a seasoned academic and researcher with a strong background in pharmaceutical chemistry and medicinal compounds. He holds a Doctorate in Chemistry from the Federal University of Rio de Janeiro, where his research focused on the design, synthesis, and pharmacological evaluation of neuroactive drug prototypes. Dr. Menegatti currently serves as a Professor at the Faculty of Pharmacy, Federal University of Goiás, Brazil, where he has been a dedicated faculty member since 2006. His expertise lies in planning and synthesizing biologically active compounds, particularly those targeting neuroactive and antipsychotic pathways. In addition to his teaching responsibilities, Dr. Menegatti is actively involved in graduate-level mentoring, guiding students in the Biological Sciences postgraduate program. His contributions extend to organizing workshops, coordinating seminars, and participating in extension activities, reflecting his commitment to advancing pharmaceutical education and research.

Research Interests

Dr. Ricardo Menegatti’s research interests lie at the intersection of pharmaceutical chemistry and medicinal chemistry, with a particular focus on the design, synthesis, and pharmacological evaluation of biologically active compounds. His work primarily revolves around the development of neuroactive drug prototypes, targeting the GABAergic system to explore potential treatments for neurological disorders such as schizophrenia, anxiety, and sleep disorders. Additionally, Dr. Menegatti is engaged in the discovery of new analgesic and antipsychotic agents, leveraging his expertise in molecular modeling and structure-activity relationships (SAR) to enhance drug efficacy and safety. His research also extends to the use of solid-phase synthesis and enzymatic catalysis in drug development, aiming to innovate in the creation of new therapeutic agents. Through his work, Dr. Menegatti contributes to the advancement of medicinal chemistry, striving to address critical challenges in the treatment of mental health disorders.

Awards and Recognition

Dr. Menegatti’s academic and research excellence has been recognized through various awards and honors throughout his career. As a recipient of scholarships from the National Council for Scientific and Technological Development (CNPq) in Brazil, he has demonstrated a strong commitment to advancing scientific knowledge. His leadership in organizing workshops and seminars further highlights his contributions to the academic community, earning him recognition among his peers and students.

Conclusion

Dr. Ricardo Menegatti’s extensive research contributions in medicinal chemistry, particularly in the development of neuroactive and antipsychotic drug candidates, make him a strong candidate for the Research for Best Researcher Award. His work has a significant geographic impact, with potential applications in global healthcare. While his research is primarily focused on pharmaceutical sciences, its implications extend to broader areas such as infectious diseases. Dr. Menegatti’s collaborative efforts, applied research, and academic leadership further solidify his suitability for this prestigious award.

Publications Top Notes

LQFM289: Electrochemical and Computational Studies of a New Trimetozine Analogue for Anxiety Treatment

  • Journal: International Journal of Molecular Sciences
  • Date: September 26, 2023
  • DOI: 10.3390/ijms241914575

Bioanalytical LC-QTOF/MS Method for a N-phenylpiperazine Derivate (LQFM05): An Anxiolytic- and Antidepressant-like Prototype Drug Applied to Pharmacokinetic and Biodistribution Studies

Antileishmanial Activity of the Chalcone Derivative LQFM064 Associated with Reduced Fluidity in the Parasite Membrane as Assessed by EPR Spectroscopy

Toxico-Pharmacological Evaluations of the Small-Molecule LQFM166: Inducer of Apoptosis and MDM2 Antagonist

 

Assoc Prof Dr. Mo’tasem Alsmadi | Biopharmaceutics

Posted on by ScienceFather
Assoc Prof Dr. Mo’tasem Alsmadi : Leading Researcher in Biopharmaceutics by Best Researcher Award

Associate Professor at Biopharmaceutics, Jordan University of Science & Technology, Jordan

Your remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.

🔬 Your successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.

🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.

Professional Profiles:

Education:

Dr. Motasem Alsmadi is an Associate Professor of Biopharmaceutics and Pharmacokinetics with a joint appointment between the Nanotechnology Institute and the Pharmaceutical Technology Department at Jordan University of Science and Technology (J.U.S.T). He earned his BSc in Pharmacy, ranking first in his class, from J.U.S.T in 2009. Subsequently, he pursued graduate studies in Pharmaceutical Technology at The University of Iowa, completing his Ph.D. in December 2014. Afterward, he worked as an Assistant Professor of Pharmaceutical Technology at the Pharmacy School at J.U.S.T until September 2020, during which time he also served as an Assistant Dean at the Pharmacy School and the Graduate Studies School.

In September 2020, Dr. Alsmadi was promoted to an Associate Professor, and in January 2023, he was appointed as a Joint Professor in the Nanotechnology Institute. In this capacity, he taught graduate-level courses and supervised master’s students at the Nanotechnology Institute, in addition to his involvement in teaching undergraduate (B.Sc and Pharm D.) and graduate (MSc and Ph.D.) courses and supervising master’s students at the Pharmacy School. Dr. Alsmadi also served as a member of the JFDA Bioavailability and Bioequivalence Committee for two years (10/2019-10/2021) as part of his national service.

Academic/Professional Particulars:

Dr. Motasem Alsmadi specializes in Pharmaceutics/Biopharmaceutics and Pharmacokinetics, as well as Nanomedicine and in vivo safety and toxicokinetics of drug delivery systems. His academic qualifications include a Ph.D. in Pharmaceutics from the University of Iowa, USA, awarded in 2014. His dissertation was titled “Physiologically based pharmacokinetic (PBPK) model of Ivermectin (IVM),” and he achieved a GPA of 3.84. Dr. Alsmadi also holds a BSc in Pharmacy from Jordan University of Science and Technology, Jordan, awarded in 2008, where he ranked 1st in his batch. In terms of academic honors and awards, Dr. Alsmadi ranked 1st in the 2003 batch of BSc. in Pharmacy at Jordan University of Science and Technology from 2003 to 2008.

Mo’tasem Alsmadi ‘s citation metrics and indices from Google Scholar are as follows:

  • Cited by: All: 208, Since 2018: 208
  • Citations: 208 (All), 208 (Since 2018)
  • h-index: 9 (All), 9 (Since 2018)
  • i10-index: 7 (All), 7 (Since 2018)

These metrics showcase the impact of Alsmadi ‘s work within the academic community, demonstrating the number of citations his publications have received and the influence of his research output.

Research:

Dr. Motasem Alsmadi’s research interests include Physiologically-based Pharmacokinetics, Biopharmaceutics and Pharmacokinetics, and Nanomedicine, with a focus on in vivo safety and toxicokinetics of drug delivery systems. In terms of publications and citations, he has authored 17 articles in international refereed journals and presented 2 conference papers. His work has garnered 147 citations on Google Scholar. Dr. Alsmadi has also been involved in securing research grants, including the Local University Fund for Master’s Thesis, where he serves as the Principal Investigator for the project “Formulation and evaluation of oral administration of cilnidipine nanocrystals for treatment of Hypertension diseases by enhancing solubility and dissolution rate” at Jordan University of Science and Technology (07/2023 – Present), with a funding of USD 7,700. Additionally, he has been a Co-Investigator for another project titled “Physiologically-Based Pharmacokinetics of a Novel Hydroxychloroquine Formulation Prepared Using Supercritical Fluid Technology for Pulmonary Administration” at Jordan University of Science and Technology (08/2021 – 01/2023), with a funding of USD 8,000.

Teaching:

Dr. Motasem Alsmadi has taught several courses, including Nano 700: Introduction to Nanoscience and Nanotechnology (taught once, excellent evaluation), Phar456: Bio Pharmaceutics and Pharmacokinetics (taught fourteen times, excellent evaluations), Phar 553: Clinical Pharmacokinetics (For Pharm D Students) (taught fifteen times, excellent evaluations), Phar401: Pharmaceutical Practical Training (taught three times, excellent evaluations), Phar 402: Community Pharmacy (For Pharm.D Students) (taught twice, excellent evaluations), and Phar 351: Pharmaceutics 1 (taught once, excellent evaluation). This demonstrates Dr. Alsmadi’s extensive experience in teaching a variety of pharmaceutical and pharmacokinetics courses, consistently earning high evaluations from his students.

Publications:

Preparation of hybrid alginate-chitosan aerogel as potential carriers for pulmonary drug delivery

  • Published in Energy in 2020 with 38 citations.

Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment

  • Published in Energy in 2020 with 34 citations.

Enhancement of the dissolution and bioavailability from freeze-dried powder of a hypocholesterolemic drug in the presence of Soluplus

  • Published in Energy in 2018 with 18 citations.

Pharmacy education in Jordan: updates

  • Published in Energy in 2017 with 17 citations.

Optimization of drugs pharmacotherapy during pregnancy using physiologically based pharmacokinetic models-an update

  • Published in Energy in 2018 with 14 citations.

Sublingual spray drug delivery of ketorolac-loaded chitosan nanoparticles

  • Published in Energy in 2018 with 14 citations.